Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia

American Journal of Alzheimer's Disease and other Dementias

Volumn 21, Issue 6, 2006, Pages 448-453

  Onor, Maria Luisa ^a   Saina, Marisa ^a   Aguglia, Eugenio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Behavioral and psychological symptoms of dementia; Quetiapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; QUETIAPINE;

ADULT; AGED; AGGRESSIVENESS; AGITATION; ARTICLE; BEHAVIOR DISORDER; BEHAVIORAL PATHOLOGY IN ALZHEIMER DISEASE RATING SCALE; CAREGIVER BURDEN; CLINICAL ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DEATH; DELIRIUM; DEMENTIA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HALLUCINATION; HUMAN; INSTITUTIONALIZATION; MALE; NEUROPSYCHIATRIC INVENTORY; NEUROPSYCHIATRY; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; TREATMENT DURATION;

EID: 33845917095     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317506294775     Document Type: Article

References (60)

1. Aarsland MK, Tandberg IE, Larsen PJ, Cummings JL. Frequency or dementia in Parkinson disease. Arch Neurology. 1996;53:538-542.
2. Gaugler JE, Edwards AB, Femia EE, et al. Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement. J Gerontology. 2005; 5B:247-255.
3. Byerly MJ, Weber MT, Brooks DL, Snow LR, Worley MA, Lescouflair E. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging. 2001;18:45-61.
4. Tune E. The role of antipsychotics in treating delirium. Curr Psychiatry Rep. 2002;4:209-212.
5. Weiner MP, Gray KF. Balancing psychosocial and psychopharmacologic measures in Alzheimer's disease. Am J Alzheimer Dis Other Demen. 1994;9:6-12.
6. Dewa CS, Remington G, Herrmann N, Fearnley J, Coering P. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther. 2002;24:1466-1476.
7. Bullock R, Saharan A. Atypical antipsychotics: experience and use in the elderly. Int J Clin Pract. 2002;56:515-525.
8. Salzman C. Treatment of the agitation of late-life psychosis and Alzheimer's disease. Eur Psychiatry. 2001; 16(suppl 1):S25-S28.
9. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol. 2001;14:499-504.
10. Sommer BR. Quetiapine-induced extrapyramidal side effects in patients with Parkinson's disease: case report. J Geriatr Psychiatry Neurol. 2001;14:99-100.
11. Tariot PN. The older patient: the ongoing challenge of efficacy and tolerability. J Clin Psychiatry. 1999;60(suppl 23):S29-S33.
12. Emsley RA. Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry. 1999;60(suppl 23):S10-S13.
13. Dewey RB Jr, O'Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology. 2000;55:1753-1754.
14. Fernandez HH, Lannon MC, Friedman JH, Abbott BP. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000;5:579-581.
15. Barak Y. Wittenberg N, Naor S, Kutzuk D, Weizman A. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr Psychiatry. 1999;40:320-325.
16. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53: 946-955.
17. Katz IR, Jeste DV, Mintzer JE. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60: 107-115.
18. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134-143.
19. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Olanzapine as a possible treatment for anxiety due to vascular dementia: an open study. Am J Alzheimers Dis Other Demen. 2004;19:81-88.
20. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205-214.
21. Marsh L, Lyketsos C, Reich SG. Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics. 2001;42:477-481.
22. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002: 13:67-73.
23. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19: 115-126.
24. Green B. Focus on quetiapine. Curr Med Res Opin. 1999;15:145-151.
25. Menza MM, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry. 1999;11:141-144.
26. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999;60:292-298.
27. Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry. 2002;63(suppl 13):21-26.
28. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002;16:128-130.
29. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002; 63:513-515.
30. Friedman JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology. 2003;28 (suppl 1):S39-S51.
31. Frucht SJ, Bernsohn L. Visual hallucinations in PD. Neurology. 2002;59:1965.
32. Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol. 2002;15:156-170.
33. Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord. 2002;17:676-681.
34. Kohmoto J, Kihira T, Miwa H, Kondo T. Effect of quetiapine fumarate on drug-induced psychosis in patients with Parkinson's disease. No To Shinkei. 2002; 54:489-492.
35. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 1999;14:484-487.
36. Madhusoodanan S, Bogunovic O. Switching elderly patients with dementia from risperidone to quetiapine: a retrospective study. Am J Alzheimer Dis Other Demen. 2006;21:169-174.
37. Garver DL. Review of quetiapine side effects. J Clin Psychiatry. 2000;61(suppl 8):31-35.
38. Sajatovic M, Brescan DW, Perez DE, et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry. 2001;62:728-732.
39. Diagnostic and Statistical Manual of Mental Disorders: Text Revision. 4th ed, Washington DC: American Psychiatric Association; 2000.
40. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria lor a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29-34.
41. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
42. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatr. 48(suppl):9-J5.
43. Caligiuri MR, Jeste DV, Latro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging. 2000;17(5):363-84.
44. Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. Clin Psychiatry. 2000;61(suppl 14):49-52.
45. Voruganti L, Cortcse L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:135-145.
46. Bogan AM, Shellhorn E, Brown ES, McDanald C, Suppes T. Switching outpatients between atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24: 351-355.
47. Jeste DV, Rockwell E, Harris M. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999;7:70-76.
48. Masand PS. Side effects oF antipsychotics in the elderly. Clin Psychiatry. 2000;61(suppl 8):439-451.
49. Weiner WJ, Minagar A, Shulman LM. Quetiapine for L-dopa-induced psychosis in PD. Neurology. 2000; 54:1538.
50. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61(suppl 4):27-32.
51. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001;35:187-191.
52. Farah A. Reduction of tardive dyskinesia with quetiapine. Schizophr Res. 2001;47:309-310.
53. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol. 2001;3: 28-32.
54. MacKnight C, Rojas-Fernandcz C. Quetiapine For sexually inappropriate hehavior in dementia. Am Geriatr Soc. 2000;48:707.
55. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-Term use nl quetiapine in elderly patients with psychotic-disorders. Clin Ther. 2000;22:1068-1084.
56. Cantillon M. De La Puente AM, Palmer BW. Psychosis in Alzheimer's Disease. Semin Clin Neuropshychiatry. 1998;3:34-40.
57. Tariot P, Gaile SE, Castelli NA, Porsteinsson AP. Treatment of agitation in dementia. New Dir Ment Health Serv. Winter 1997:109-123.
58. Tarqum SI. New Rx For psychoses in Alzheimer's. Parkinsons. Contemp Longterm Care. 2001;24:39-40.
59. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. Clin Psychopharmacol. 2000; 20:54-60.
60. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinsons disease. J Neuropsychiatry Clin Neurosci. 1998;10:216-219.